Advanced breast cancer
Trovati 39 articoli
- Breast cancer: change in HER2 status after treatment with Trastuzumab
- Researchers at The University of Texas MD Anderson Cancer Center have discovered that when treated with Herceptin prior to surgery, 50 percent of HER2 positive, breast cancer patients showed no signs of disease at the time of surgery. However, of those women who had residual disease, about one-th... (Leggi Articolo)
- Microangiopathic hemolytic anemia in patients treated with Bevacizumab plus Sunitinib
- The safety and maximum tolerated dose ( MTD ) of sunitinib malate( Sutent ) in combination with Bevacizumab ( Avastin ) has been assessed in patients with metastatic renal cell carcinoma ( mRCC ) in a phase I study, exploring 3 cohorts using a fixed dose of Avastin at 10 mg/kg/IV every 2 weeks an... (Leggi Articolo)
- Additional trials have shown increased mortality and/or tumor progression with
- On November 8, 2007, the Aranesp ( Darbepoetin alpha ) and Epogen / Procrit ( Epoetin alpha ) labeling were revised to describe the results of 6 studies showing increased mortality and more rapid tumor progression in patients with cancer receiving ESAs ( erythropoiesis-stimulating agents ). A... (Leggi Articolo)
- Hepatocellular carcinoma: Nexavar significantly prolongs overall survival
- Sorafenib ( Nexavar ) tablets has significantly extended overall survival in patients with hepatocellular carcinoma ( HCC ), or primary liver cancer versus those taking placebo by 44% ( HR=0.69; p-value=0.0006 ). The Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol ( SH... (Leggi Articolo)
- Advanced breast tumor: FDA has approved Tykerb
- The FDA ( Food and Drug Administration ) has approved Tykerb ( Lapatinib ), a new targeted anti-cancer treatment, to be used in combination with Capectabine ( Xeloda ), another cancer drug, for patients with advanced, metastatic breast cancer that is HER2 positive. The combination treatment is ... (Leggi Articolo)
- Aromatase inhibitors linked to increase in survival in advanced breast cancer
- Aromatase inhibitors, a type of hormone therapy used to treat advanced breast cancer in postmenopausal women, result in a small but significant increase in overall survival when compared to other hormone treatments, according to a new systematic review of studies. In addition, aromatase inhib... (Leggi Articolo)
- FDA has strengthened boxed warnings for erythropoiesis-stimulating agents
- The FDA ( Food and Drug Administration ) has approved revised boxed warnings and other safety-related product labeling changes for erythropoiesis-stimulating agents ( ESAs ), which treat certain types of anemia. These new statements address the risks that the drugs Aranesp ( Darbepoetin alpha ), ... (Leggi Articolo)
- Higher risk of dying from prostate cancer linked to excess weight and adult weight gain
- A study found that obesity increases the risk of death from prostate cancer, even though it does not increase the overall risk a man will be diagnosed with the disease. The study has shown that higher body mass index ( BMI ) and weight gain in adulthood correlated strongly with increased risk o... (Leggi Articolo)
- Advanced breast cancer: Neuvenge, an active cellular immunotherapy
- Dendreon announced publication of results from a Phase 1 study of Neuvenge, an investigational active cellular immunotherapy, in the Journal of Clinical Oncology. The article highlights the safety profile, immune response and clinical activity of Neuvenge in women with HER2/neu-positive breast ... (Leggi Articolo)
- FDA has approved Ixempra for patients with advanced breast cancer
- The FDA ( Food and Drug Administration ) has approved Ixempra ( Ixabepilone ), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs. Ixempra was approved for use in combination with another cance... (Leggi Articolo)
- Lapatinib in combination with Paclitaxel as first-line treatment for patients with metastatic or relapsed advanced breast cancer
- Paclitaxel ( Taxol ) is one of the most commonly used chemotherapies in breast cancer. Therefore, the evaluation of Lapatinib ( Tykerb ) in combination with this treatment is of high importance. A large, randomized, multicenter, prospective trial evaluated a total of 580 patients either negat... (Leggi Articolo)
- Relationship between inflammatory processes and tumor formation
- Researchers are closely studying the link between inflammatory processes and tumor formation, while others are investigating anti-inflammatory drugs as a means to prevent and treat cancer. Antihistamine and anti-inflammatory drug use associated differently for high-grade versus low-grade gli... (Leggi Articolo)
- Inflammation markers identify fatigue in breast cancer survivors
- Researchers at the University of California - Los Angeles ( UCLA ) have defined conditions associated with disabling fatigue that persists for years in almost a third of breast cancer survivors. The study is published in the Clinical Cancer Research. " Studies have identified a biological ... (Leggi Articolo)
- Europe: Herceptin for early-stage in HER2-positive breast cancer
- The European Commission has approved Herceptin ( Trastuzumab ) for patients with early-stage HER2-positive breast cancer following surgery and standard chemotherapy. The approval is based on impressive results from the international HERA ( HERceptin Adjuvant ) study which showed Herceptin fo... (Leggi Articolo)
- Interleukin-12 may help antibody-based drugs fight cancer
- A study suggests that antibody-based cancer drugs might help patients more if they are given with substances that stimulate the immune system. This study is the first to indicate that the drug Trastuzumab, also known as Herceptin, may work better when it is followed by injections of interleuk... (Leggi Articolo)
- Raloxifene and Tamoxifen are both effective in reducing the risk of invasive breast cancer but have different side effects
- Two studies found that Raloxifene ( Evista ) and Tamoxifen ( Novaldex ) are both effective in reducing the risk of invasive breast cancer, but each has potential disease and quality of life side effects that women and their physicians will need to consider. The papers are published in the JAMA... (Leggi Articolo)
- Apo2L selectively activates death receptors in cancer cells
- Researchers at The University of Texas M. D. Anderson Cancer Center have evaluated a new type of drug that activates "death" receptors on cancer cells, and have found it to be both safe and suggestive of potential benefit. The drug, human Apo2L/TRAIL ( Apo2L 0 ), produced only minimal side ef... (Leggi Articolo)
- Pancreatic cancer: Gemcitabine added to standard therapy after surgery improves survival
- A multicenter study has found that adding Gemcitabine to standard therapy after surgery significantly improves survival for patients with the most common form of pancreatic cancer. More than 500 patients were enrolled in the study from 1998 to 2002. Thirty-two percent of study participan... (Leggi Articolo)
- Basic research at the Max Planck Institute of Biochemistry leads to a novel cancer therapy
- Axel Ullrich, at the Max Planck Institute of Biochemistry in Martinsried, Germany, already showed at the beginning of the 1990s that blocking blood vessel development in a tumour slows down its growth, and shrinks its tissue. This fundamental principle led to the development of Sutent ( Sunit... (Leggi Articolo)
- Advanced breast cancer: Tykerb an alternative to Herceptin
- A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks with Capecitabine alone, p=0.00032 ) in women with refractory advanced or metastatic ErbB2 positive ... (Leggi Articolo)
- Advanced breast cancer: Tykerb an alternative to Herceptin
- A Phase III study has shown that Lapatinib ( Tykerb ) and Capecitabine ( Xeloda ) versus Capecitabine alone nearly doubled time to progression ( 36.9 weeks in the combination arm versus 19.7 weeks with Capecitabine alone, p=0.00032 ) in women with refractory advanced or metastatic ErbB2 positive ... (Leggi Articolo)
- Advanced HER2-positive breast cancer: Herceptin added to hormonal therapy prolongs progression-free survival
- Data from TAnDEM study have shown that the addition of Trastuzumab ( Herceptin ) to the hormonal therapy, Anastrozole ( Arimidex ), improves progression-free survival for patients whose advanced breast cancer is hormone receptor-positive, as well as HER2-positive. Hormone receptor-positive br... (Leggi Articolo)
- Letrozole prolongs disease-free survival in early breast carcinoma
- The treatment with Letrozole ( Femara ) of postmenopausal women with early breast cancer prolonged disease-free survival by reducing the risk of recurrence an additional 19% over that offered by Tamoxifen ( Nolvadex ) when used as initial treatment after surgery, according to data from the Breast... (Leggi Articolo)
- Advanced breast cancer, Taxotere more effective than Paclitaxel
- The treatment with Docetaxel ( Taxotere ) significantly improved overall survival and median time to disease progression compared with Paclitaxel in women with advanced breast cancer whose cancer had progressed after previous treatment with an anthracycline-based therapy. The study showed a s... (Leggi Articolo)
- Curcumin halts spread of breast cancer in mice
- Researchers at The University of Texas M. D. Anderson Cancer Center found that curcumin, the main ingredient of turmeric and the compound that gives curry its mustard-yellow color, inhibits metastasis to the lungs of mice with breast cancer. The study, published in the journal Clinical Cancer... (Leggi Articolo)
- Can healthcare systems afford Herceptin for early breast cancer ?
- A research into the cost of using the breast cancer drug Herceptin ( Trastuzumab ) warns that healthcare authorities and the organisations advising them should not rush to prescribe it for early breast cancer without working out extremely carefully the budget implications and cost-effectiveness o... (Leggi Articolo)
- Early-stage breast cancer, Herceptin after adjuvant chemotherapy improves disease-free survival
- Herceptin ( Trastuzumab ), a recombinant monoclonal antibody against HER2, previously shown to prolong survival in advanced breast cancer, reduced the recurrences in patients with early-stage disease when given for one year following standard chemotherapy. These are the encouraging findings in... (Leggi Articolo)
- Ovarian cancer, km23 protein may be early warning
- Researchers at Penn State College of Medicine found a signal that could lead to earlier detection and treatment of ovarian cancer. The Penn State team of scientists led by principal investigator Kathleen M. Mulder, studied "km23," a protein that helps to direct protein traffic in the cell. ... (Leggi Articolo)
- Cell surface enzyme matriptase can cause cancer
- Researchers at the National Institute of Dental and Craniofacial Research ( NIDCR ) and colleagues found in animal studies that a single, scissor-like enzyme called matriptase, when left to its own devices, can cause cancer. This finding, published in the journal Genes and Development, marks ... (Leggi Articolo)
- Chemotherapy after surgery extends survival for patients with advanced endometrial cancer
- A study has shown for the first time that giving two chemotherapy drugs to women with advanced endometrial cancer after surgery reduced the risk of recurrence by 29% and extended survival by 32% compared with women who received whole abdominal irradiation. The findings could improve the care f... (Leggi Articolo)
- Herceptin plus chemotherapy reduces risk of recurrence in early-stage HER2-positive breast cancer
- A large phase III trial in early-stage HER2-positive breast cancer has shown that adding Herceptin ( Trastuzumab ) to chemotherapy significantly reduces the risk of disease recurrence compared to chemotherapy alone. This study follows three earlier phase III studies which also confirmed Herc... (Leggi Articolo)
- Novartis, new products portfolio
- Novartis has a comprehensive portfolio of cardiovascular products both in the market ( Diovan and Lotrel ) as well as in development ( such as LAF237 and SPP100 ), for the treatment of hypertension, dyslipidemia and diabetes. Other compounds in development include APP018 ( D-4F ), an oral Apo ... (Leggi Articolo)
- Metronomic chemotherapy plus antiangiogenesis drug has activity in advanced breast cancer
- Chemotherapy given in low, frequent doses – a novel strategy called "metronomic" delivery – achieved partial shrinkage of disease in some advanced breast cancer patients when given concurrently with an angiogenesis inhibitor. In a pilot study of 55 patients, the combination of low-dose chemot... (Leggi Articolo)
- Surviving breast cancer: does a woman's marital status matter ?
- Research has shown that being single, married or divorced can influence cancer survival, but a new study shows marital status appears to have no impact on the outcome for women with breast cancer who are treated with lumpectomy and radiation. " In the past, we've looked at survival rates for m... (Leggi Articolo)
- E7389, a potential new therapy for the treatment of breast cancer
- Researchers presented preliminary safety and efficacy data for E7389 in the treatment of advanced, refractory breast cancer. E7389 is a synthetic analog of halichondrin B ( HB ), which is a natural product shown in preclinical studies to have highly potent anti-cancer activity in vitro and in ... (Leggi Articolo)
- EphA2, a novel target for glioblastoma multiforme
- Researchers at Wake Forest University Baptist Medical Center have identified a second promising treatment target for glioblastoma multiforme, one of the most deadly types of brain tumors. The research results are reported in the Molecular Cancer Research. " We've found that a particular pr... (Leggi Articolo)
- Serious complications linked to Docetaxel and Doxorubicin regimen in breast carcinoma
- A clinical trial demonstrated that the chemotherapy regimen of Doxorubicin plus Docetaxel ( Taxotere ), used to treat breast cancer, was associated with an increased risk of serious complications, resulting in the premature termination of the trial. Combinations of certain breast cancer drug c... (Leggi Articolo)
- Breast tumor patients treated with adjuvant therapy: Zoledronic Acid improves bone mineral density
- Zoledronic Acid ( Zometa ), an intravenous bisphosphonate, was shown to inhibit aromatase inhibitor-induced bone loss in postmenopausal women treated with Letrozole ( Femara ) in the adjuvant breast cancer setting. Final data of the primary endpoint of 12-month bone mineral density ( BMD ) dem... (Leggi Articolo)
- Osteonecrosis of the jaw and bisphosphonates
- Bisphosphonates are drugs commonly used to prevent and treat osteoporosis in post-menopausal women. They are widely used in the management of advanced cancers that have metastasized to the bone, where the disease often causes bone pain and possibly even fractures. Several cancers can metast... (Leggi Articolo)
